Face Serum Regulatory Labelling: INCI, Net Weight & Market-Specific Requirements

Overview #

Regulatory labelling for face serums is not a branding exercise. It is a compliance gate — and it is the one area where we see finished, approved formulations get held at customs or pulled from shelves because someone on the brand side assumed the rules were the same across markets. They are not. INCI nomenclature, net weight declaration format, and mandatory warning text all vary by jurisdiction, and the differences are specific enough that a single master label rarely survives intact across EU, US, and APAC markets. What follows is what we walk every brand partner through before we print a single proof.

INCI Nomenclature: What the Rules Actually Require #

INCI — International Nomenclature of Cosmetic Ingredients — is the global standard, but “global” is doing a lot of work in that sentence. The EU Cosmetics Regulation 1223/2009 mandates INCI listing on-pack in descending order of weight at time of manufacture, with ingredients present at or below 1% listed in any order after those above 1%. That last part matters more than most brands realise. We have had clients argue about ingredient positioning on pack for marketing reasons — “can we move the hyaluronic acid higher?” — and the answer is always: only if the concentration justifies it.

The FDA takes a different approach. Under FDA Cosmetics Guidelines, the US requires ingredient declaration under the Fair Packaging and Labeling Act, also in descending order, but the enforcement mechanism and the consequences of non-compliance are structurally different from the EU. In the EU, non-compliant labelling can trigger a product recall coordinated through the CPNP notification system. In the US, the consequences are more typically enforcement letters and market withdrawal — slower, but still commercially damaging.

China’s NMPA Cosmetic Regulation adds another layer. Since the 2021 Cosmetic Supervision and Administration Regulation (CSAR) came into force, China requires ingredient listing in Chinese characters alongside INCI names for registered products. For serums containing “new cosmetic ingredients” — a category that includes many peptides and novel actives — full registration dossiers are required before the ingredient can appear on a Chinese label at all. We have had projects delayed by 8–14 months because a brand wanted to include an ingredient that had not yet cleared NMPA’s new ingredient pathway.

Japan is the one that catches brands off guard most often. The Japanese standard uses a hybrid of JSCI (Japanese Standard of Cosmetic Ingredients) names and INCI, and certain ingredients have mandatory local-language names that do not map cleanly to their INCI equivalents. When we brief our labelling team on a Japan-bound serum, we run a separate JSCI cross-reference check. It adds time. It is not optional.

Net Weight Declaration: The Details That Cause Customs Failures #

Net weight on a face serum is not just “write the fill volume on the box.” The format, placement, and unit requirements differ by market, and getting this wrong is one of the most common reasons we see shipments flagged.

In the EU, net weight must be expressed in metric units (grams or millilitres), with a minimum font height of 6mm for packages with a surface area greater than 80cm². The e-mark (ℯ) can be used to indicate that the quantity was determined under EU average fill rules — but only if the filling line is operating under a certified average system. We run our filling lines under ISO-certified average quantity control, so we can offer the e-mark, but not every contract manufacturer can. Worth asking your OEM partner directly.

For the US market, the Fair Packaging and Labeling Act requires dual declaration — both metric and US customary units (fl oz for liquids, oz for solids). A 30ml serum must read “1.0 fl oz (30 mL)” or equivalent. The metric unit can follow in parentheses, but both must appear. We have seen brands submit label proofs with metric-only declarations for US SKUs. That is a compliance failure before the product leaves the warehouse.

China requires net content in metric units, and the declaration must appear on the main display panel. For serums in dropper bottles — which is most of what we produce in this category — the declared volume must match the actual fill within the tolerances specified under GB 5296.3. Our QC team checks fill weight on every production batch against the declared net content, with a tolerance of ±3% for volumes under 50ml.

One thing we push back on regularly: brands who want to declare net weight in “doses” or “applications” rather than grams or millilitres. Some markets permit supplementary dose information, but it cannot replace the mandatory metric declaration. It can sit alongside it. Not instead of it.

Mandatory Warning Text and Restricted Ingredient Declarations #

This is where SCCS Scientific Opinions become directly relevant to label copy. The SCCS issues opinions on cosmetic ingredient safety that feed directly into EU Annex restrictions — and those restrictions often carry mandatory on-pack warning statements.

Retinol is the clearest current example. Following the SCCS opinion on vitamin A in cosmetics, the EU introduced concentration limits and mandatory warning text for retinol-containing leave-on products. Serums with retinol above 0.3% now require a specific warning statement on pack. We have reformulated several serum SKUs in the past two years specifically to stay below that threshold and avoid the warning text — not because the higher concentration is unsafe, but because the warning text creates a consumer perception problem that most brand partners are not willing to manage. For more on how we handle retinoid concentration and stability trade-offs, see our retinoid technology formulation guide.

Fragrance allergens are another mandatory disclosure area in the EU. The current EU Cosmetics Regulation requires individual listing of 26 fragrance allergens above 0.001% in leave-on products. The proposed revision under the EU Fragrance Allergen Regulation would expand this list significantly — we are tracking that closely because it will affect a large number of our current serum formulations that use natural fragrance complexes.

Alpha-hydroxy acids in serums trigger mandatory pH and concentration warnings in several markets. In the EU, AHA-containing rinse-off products above 3% and leave-on products above 10% require specific advisory text. For our acid serum formulations, we always confirm the final pH and AHA concentration before finalising label copy — because the warning text requirement is triggered by the combination of both parameters, not either one alone. See our acid exfoliation technology documentation for how we manage this in formulation.

Where Most Brands Get This Wrong #

Honestly, the single most common failure mode we see is brands treating labelling as a post-formulation task. They finalise the formula, approve the packaging, and then hand the ingredient list to a regulatory consultant two weeks before the planned ship date. At that point, if there is a compliance issue — a restricted ingredient, a missing warning statement, a net weight format error — the timeline collapses.

We require label copy sign-off as part of our pre-production checklist, not as a separate downstream step. For multi-market launches, we build a labelling matrix at the brief stage: one row per market, columns for INCI requirements, net weight format, mandatory warnings, and any market-specific registration requirements. It takes half a day to build. It has saved several projects from expensive reprints.

One project memory that stays with us: a brand launching a niacinamide-peptide serum across EU and GCC markets simultaneously. The GCC version required Arabic text on the primary label, which the brand had not factored into the label dimensions. The EU version required a specific allergen declaration for a botanical extract in the formula that the brand had not flagged as a fragrance component. Both issues surfaced at label proof stage — four weeks before planned production. We caught them. But only because we were running the labelling matrix in parallel with formulation sign-off, not after it.

The GCC market, incidentally, follows Gulf Standardization Organization (GSO) requirements that align broadly with EU INCI standards but have specific requirements around halal certification claims and Arabic language labelling that are entirely separate from the formulation compliance question. If you are planning a GCC launch, that is a separate workstream.

Designing a 12-Week Consumer Perception and Efficacy Study for Face Serums #

This is where the regulatory labelling question connects to claims substantiation — because every on-pack claim needs to be defensible, and in the EU and increasingly in the US, “defensible” means documented evidence.

For a face serum, a 12-week study design that we have used with brand partners typically runs as follows. Recruit 35–50 subjects (we have run studies at n=42 and n=48 for this category), female, ages 30–55, Fitzpatrick skin types II–IV, with self-reported concerns matching the product’s target claims — typically fine lines, uneven tone, or hydration. Exclude subjects with active dermatological conditions, recent cosmetic procedures within 3 months, or current use of prescription retinoids.

Baseline measurements at week 0 include: TEWL (transepidermal water loss) via Tewameter, skin hydration via Corneometer, melanin index via Mexameter, and standardised photography under controlled lighting (cross-polarised and parallel-polarised). We use a Canfield VISIA system for photography when the budget allows — it gives you UV fluorescence and texture mapping alongside standard imaging. When budget is tighter, a fixed-position ring-light setup with consistent subject positioning achieves acceptable reproducibility for before/after imagery.

Measurement timepoints at weeks 4, 8, and 12. Consumer self-assessment questionnaire at weeks 4 and 12 — we use a 7-point Likert scale for perceived improvement across 6–8 attributes. The questionnaire design matters more than most brands appreciate. Vague questions like “does your skin feel better?” produce data that is hard to use in claims. Specific questions like “my skin feels more hydrated immediately after application” and “I notice a visible reduction in fine lines around my eyes” give you claim-specific consumer perception data.

One clinical reference point we use internally: a double-blind, randomised, vehicle-controlled study (n=44, 12 weeks) evaluating a 5% niacinamide serum formulation showed a 23% reduction in melanin index versus vehicle control, and a 31% improvement in self-assessed skin tone evenness at week 12. That study design — vehicle-controlled, blinded, with both instrumental and consumer-reported endpoints — is the format that holds up best under regulatory scrutiny for claims like “visibly evens skin tone in 12 weeks.”

Photography protocol deserves its own paragraph because it is where study data most often gets challenged. Consistent lighting angle, consistent subject positioning (chin rest, fixed camera distance), consistent skin preparation (no moisturiser for 2 hours before imaging), and consistent image processing (no post-processing beyond standardised colour calibration). We have seen brand-commissioned studies where the before images were taken under harsher lighting than the after images. That is not a study. That is marketing. Reviewers at the FDA and EU notified bodies know what to look for.

For the statistical analysis, we use paired t-tests for within-group comparisons and ANCOVA for between-group comparisons where a vehicle control arm is included. A p-value threshold of <0.05 is standard. Effect sizes matter too — a statistically significant result with a small effect size is not necessarily a commercially useful claim. We are still working out the right way to communicate that to brand partners who see “p<0.05” and assume the claim is bulletproof. It is not always that simple.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? Those are the first two questions we ask when a serum brief comes in — because the answers determine the labelling architecture before we touch the formula.

If you are launching EU-first, we build the INCI list to EU Annex compliance from day one, flag any ingredients approaching restriction thresholds, and confirm mandatory warning text requirements before the formula is locked. For a retinol serum, that means confirming final retinol concentration against the 0.3% leave-on threshold. For an AHA serum, it means confirming pH and acid concentration against the advisory text triggers.

If you are launching into China simultaneously, we need to know at brief stage — not after formulation sign-off. The NMPA registration pathway for standard cosmetics takes 3–6 months for domestic registration; for products containing new cosmetic ingredients, add 12–18 months minimum. We have had brands come to us with a formula they developed elsewhere that contained an ingredient not yet approved under NMPA’s new ingredient list. The options at that point are reformulate or abandon the China launch. Neither is a good conversation to have late in the project.

Net weight and fill volume decisions also happen at brief stage. A 30ml dropper serum and a 30ml pump serum have different fill tolerances, different label real estate constraints, and different net weight declaration formats depending on the packaging type. We will not finalise label dimensions until the packaging format is confirmed.

Frequently Asked Questions #

Q: We want to list our hero peptide first on the INCI — can we do that?

Only if it is genuinely the highest-concentration ingredient by weight at manufacture, which for most peptides it is not. Peptides are typically active at 0.5–5% in a serum formula. If your water phase is 70%+ of the formula, water (Aqua) goes first. We can discuss concentration strategy if positioning matters to you, but we will not falsify the order.

Q: Our US and EU labels are almost identical — can we use one master label for both?

Almost never works cleanly. The US requires dual metric/imperial net weight declaration; the EU does not use imperial units. The EU may require specific warning text that the US does not mandate. And the font size minimums differ. In practice, we produce market-specific label files from a shared master data sheet — same INCI list, different format execution per market.

Q: How long does a 12-week consumer study take from brief to final report?

Typically 20–24 weeks total. Recruitment and screening takes 4–6 weeks, the study runs 12 weeks, and data analysis and report writing takes 4–6 weeks. If you need the data to support a launch claim, it needs to be commissioned before formulation is finalised — not after.

Q: Do we need a separate study for each market’s claims?

Not necessarily, but the study design needs to be robust enough to hold up in each target market. EU claims substantiation under the EU Cosmetics Regulation 1223/2009 requires documented evidence proportionate to the claim. A study with n=42, 12 weeks, and both instrumental and consumer-reported endpoints is generally sufficient for standard efficacy claims across EU, US, and most APAC markets. China has additional requirements for specific claim categories — “whitening” claims, for example, require separate substantiation under NMPA rules.

Q: Can we use supplier-provided clinical data for our claims?

You can reference it, but we would not rely on it exclusively. Supplier studies are typically conducted on the raw ingredient, not your finished formula at your specific concentration. The FDA and EU regulators expect claims to be substantiated for the finished product as sold. Supplier data is useful supporting context. It is not a substitute for finished-product evidence.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.